Carboquone is an alkylating drug that is utilized in the treatment of malignant cancers of the lung, stomach, ovary, lymphomas and chronic myeloid leukemia. It is typically given by IV or by mouth.
This drug is used for chemotherapy. Plasma levels of anticonvulsants may become subtherapeutic when therapy takes place. In studied about advanced ovarian cancer, there was a negative effect when pyridoxine was used in combination with altretamine and carboquone. If you are pregnant or breastfeeding, you should first consult your doctor before taking the said drug. It is a kind of drug that can also affect the fertility of both men and women.
In one study, patients with small cell carcinoma of the lung were treated with large doses of Carboquone (CQ). About 0.4mg/kg of CQ was administered at first, and 0.2mg/kg of CQ was re-administered at intervals of 5 weeks. All subjects were also dosed with OK-432 1 KE/body weight daily. Twelve of these patients had also radiotherapy within 1 week after the second shot of CQ. Two cases showed a complete response and nine showed a partial response after the therapy, with a response rate of 79%. After radiotherapy, five patients showed complete response and seven patients showed partial response. The response rate was 100%.
The survival time was 39 weeks for all cases, 26 weeks for five patients with extensive disease and 56 weeks for nine cases with limited disease. Complete responders survived longer than partial responders. The results suggest the administration of a large dose of CQ for the treatment of small cell carcinoma. The combination of radiotherapy with chemotherapy is also seen to be more effective.
